FDA Oncology Therapeutics Office Planned; Drug, Biologics Units Will Merge
Executive Summary
FDA is understood to be finalizing a plan for a new office of cancer therapeutics that would merge the current drug and biologics review groups within the Center for Drug Evaluation & Research's Office of New Drugs